Parallel: 2×12, Xover: 12 [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2019-06-14 20:43 (831 d 07:04 ago) – Posting: # 20327
Views: 1,603

Hi Olivbood,

» The guideline specifies that "At a minimum, 12 subjects should be enrolled in each treatment arm." I deduce from it that this is the minimal sample size considering a parallel design study.

Correct.

» Alternatively, for a classic 2x2 cross-over study the minimal sample size should be 12 subjects in total since each subject will experience both fed and fasted status.
»
» Is my understanding correct?

Correct, again.

I both cases I would include a bit more subjects to be protected against eventual dropouts. I guess the FDA wouldn’t be amused to get a study in 11 subjects although the guidance clearly states “12 enrolled”.

Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
21,691 posts in 4,534 threads, 1,541 registered users;
online 2 (0 registered, 2 guests [including 2 identified bots]).
Forum time: Thursday 03:48 CEST (Europe/Vienna)

Learning is a lifetime process, but there comes a time
when we must stop adding and start updating.    Robert Brault

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5